We found that the antagonistic balance between MDSC and Tregs limits the beneficial effect of iNOS inhibition on tumor immunity, but that it can be overcome by targeting Tregs simultaneously with an iNOS inhibitor and low-dose cyclophosphamide [72]. The gene discussed is NOS2; the disease is neoplasm.